Posts by: Jonathan Grinstein

Jonathan Grinstein

February 15, 2019February 15, 2019

Neurofilament Light Chain Levels in Blood of Value as Biomarker of MS Activity and Treatment Response, Study Finds

News

Blood levels of a nerve cell-derived component known as neurofilament light chain (NfL) could be used as a biomarker of disease severity and treatment response in patients with relapsing-remitting ... Read more

February 14, 2019February 14, 2019

FDA Asked to Place Cannabis-based Therapy for Progressive MS on Fast Track, MMJ Holdings Says

News

A request for a potential cannabis-based treatment for multiple sclerosis to be given Fast Track designation, speeding its development as it readies to enter clinical testing, is now before the U.S. Food and Drug Administration ... Read more

February 13, 2019February 13, 2019

Early-life Antibiotic Use Disrupts Gut Microbiota and Immune System, MS Rat Study Finds

News

Early-life use of antibiotics disrupts gut microbiota in a rat model of multiple sclerosis (MS) and provokes nervous system autoimmunity, ultimately aggravating disease severity, new research shows. Results also indicate ... Read more

February 12, 2019February 14, 2019

MMP-9 Protein a Possible Marker of PML in Tysabri-treated RRMS Patients, Study Suggests

News

A protein called MMP-9 could be a predictive marker of progressive multifocal leukoencephalopathy development in patients with relapsing-remitting multiple sclerosis (RRMS) who are being treated with Tysabri (natalizumab), a study suggests. The study, ... Read more

February 11, 2019February 14, 2019

Social Cognition Issues Linked to Damage in Specific Brain Region in RRMS Patients, Study Shows

News

Issues with social cognition can occur in relapsing-remitting multiple sclerosis (RRMS) patients even without the presence of cognitive impairment, and are related to damage in a specific brain region known ... Read more

February 11, 2019February 11, 2019

Petition Urges NHS England to Make Ocrevus Available for PPMS Patients

News

More than 21,000 people have signed a petition calling for Ocrevus (ocrelizumab) to be made available on the National Health Service (NHS) in England for people with primary progressive ... Read more

February 8, 2019February 8, 2019

#ACTRIMS2019 – Upcoming Forum Will Include Interactive, Case-based Discussion About MS Therapeutic Landscape

News

The Physicians’ Education Resource will host an interactive, case-based discussion on the latest therapeutics in multiple sclerosis (MS). The free educational program, part of the 2019 Americas Committee for Treatment and ... Read more

February 7, 2019February 12, 2019

Discovery of Immune Cell Subtypes in Mice is an MS ‘Breakthrough,’ Researcher Says

News

Previously unknown immune cell subtypes are present in the inflamed brain of mice models of multiple sclerosis, a new study reports. According to the researchers, these subsets of myeloid cells ... Read more

February 6, 2019February 7, 2019

Traditional Dysphagia Therapy Improves Swallowing Function in MS Patients, Pilot Study Shows

News

Rehabilitation using traditional dysphagia therapy improved swallowing function in multiple sclerosis patients with dysphagia, a pilot study shows. Traditional dysphagia therapy, also known as TDT, is a potential rehabilitation strategy ... Read more

February 5, 2019February 5, 2019

MS May Raise Risk of Deep-vein Blood Clots, Possibly by Limiting Mobility, Study Says

News

People with multiple sclerosis may be twice as likely to develop deep-vein blood clots, a condition known as venous thromboembolism, than healthy people do, a study reports. But data ... Read more

February 4, 2019February 5, 2019

Gait Disorders and Depression at Onset May Delay Time to MS Diagnosis, Study Finds

News

Awareness of certain symptoms, particularly gait disorders and depression, could be critical for reducing the time it takes to diagnose multiple sclerosis (MS) after a patient first contacts a healthcare ... Read more

February 1, 2019February 4, 2019

Medication Use in RRMS Patients Highlights Importance of Better Treatment Management, Study Says

News

Patients with relapsing-remitting multiple sclerosis (RRMS), particularly those with multiple conditions who are more severely disabled, are more likely to be using several medications at the same time, a study ... Read more

January 31, 2019February 7, 2019

Anxiety and Depression Linked to Cognitive Issues in MS, Other Diseases, Study Finds

News

Anxiety and depression are associated with lower cognitive abilities in patients with multiple sclerosis other and immune-mediated inflammatory diseases such as inflammatory bowel disease and rheumatoid arthritis, a study shows. These ... Read more

January 30, 2019January 30, 2019

Canadian RRMS Patients Less Likely to Discontinue Treatment with Oral Gilenya, Compared to Injectable or Infusible Therapies

News

Multiple sclerosis (MS) patients in Canada are more likely to comply with their treatment plan and less likely to discontinue the use of the oral disease-modifying treatment Gilenya (fingolimod), compared ... Read more

January 28, 2019February 1, 2019

Decline in Brain Volume Driven by Gray Matter Atrophy in MS Patients Despite Tysabri Treatment

News

The progressive decline in brain volume in multiple sclerosis (MS) patients, despite treatment with the disease-modifying therapy Tysabri (natalizumab), is driven by atrophy — shrinkage due to the degeneration of cells ... Read more

January 28, 2019January 29, 2019

Altered Oligodendrocyte Diversity Contributes to Multiple Sclerosis, Study Suggests

News

Subpopulations of oligodendrocytes — cells that produce the myelin sheath that protects nerve fibers — are altered in patients with multiple sclerosis, a study shows. These findings suggest that oligodendrocyte ... Read more

January 25, 2019January 28, 2019

Positive Safety Data Reported for High-dose MS Treatment Candidate Temelimab

News

GeNeuro has reported positive data from a Phase 1 clinical trial (NCT03574428) evaluating the safety and tolerability of high doses of GNbAC1, developed for the treatment of neurological and autoimmune disorders, ... Read more

January 24, 2019January 31, 2019

New Products Intended to Stimulate Feet of MS Patients

News

Naboso Technology has expanded its product offerings with new insoles and training mats specifically designed to stimulate the nervous system through the skin on the bottom of the feet. The ... Read more

January 23, 2019January 23, 2019

Novartis, Oxford’s Big Data Institute Team to Better Understand, Treat Complex Diseases

News

Novartis and the University of Oxford’s Big Data Institute (BDI) have established an alliance to advance the use of medical data for spotting disease patterns and assessing patients’ responses to ... Read more

January 22, 2019January 29, 2019

Certain Treatments Linked to Lower Risk of Secondary Progressive MS, Study Shows

News

Initial treatment of relapsing-remitting multiple sclerosis (RRMS) with Gilenya (fingolimod), Tysabri (natalizumab), or Lemtrada (alemtuzumab) is associated with a lower risk of conversion to secondary progressive multiple sclerosis (SPMS), ... Read more

January 21, 2019January 28, 2019

Fatigue More Common in Progressive MS Patients, Survey Shows

News

Fatigue is more prevalent among patients with progressive multiple sclerosis (MS), according to a study that surveyed patients on fatigue and factors related to it. In addition, increased fatigue ... Read more

January 18, 2019January 21, 2019

Small Molecule Shows Ability to Limit Autoimmune Response in MS, Mouse Study Reports

News

A small molecule called Sephin1 may be able to significantly delay harm to neurons in multiple sclerosis (MS) by protecting oligodendrocytes, limiting the autoimmune response, a mouse study reports. The study, ... Read more

January 16, 2019January 23, 2019

Researcher Wins Barancik Prize for Study of Blood Factors’ Role in MS

News

Katerina Akassoglou, PhD, a leading neurology researcher at the Gladstone Institutes at the University of California, San Francisco (UCSF), won the 2018 Barancik Prize for Innovation in Multiple Sclerosis ... Read more

January 14, 2019January 16, 2019

Tecfidera Effective in East Asian RRMS Patients, Phase 3 Trial Shows

News

Tecfidera (dimethyl fumarate) demonstrated strong efficacy in Japanese and other East Asian patients with relapsing-remitting multiple sclerosis (RRMS), a Phase 3 clinical trial shows. These results are consistent with previous ... Read more

January 10, 2019January 14, 2019

Targeting Gut Immune Cells May Alleviate Brain Inflammation in MS, Study Suggests

News

A type of immune cell from the gut can reduce brain inflammation in people with multiple sclerosis (MS), and increasing the numbers of these cells in a mouse model ... Read more

January 9, 2019January 11, 2019

BrainStorm Expands Production of Autologous Stem Cell Therapy NurOwn for Phase 2 Trial in Multiple Sclerosis

News

BrainStorm Cell Therapeutics announced that the production of its therapy NurOwn will be expanded to support upcoming clinical trials, namely a Phase 3 trial in amyotrophic lateral sclerosis (ALS) and a ... Read more